Cerus Corporation 该公司是一家生物医药产品公司，专注于“拦截血液系统”的商业化推广，以加强血液安全。设计该“拦截系统”是为了灭活原本用于输血的捐献血液成分中的血源性病原体。目前，该公司在欧洲，俄罗斯，中东和世界其他地区中的选定国家中销售血小板和血浆的“拦截系统”。该公司还在美国和其他国家寻求监管机构批准其血小板和血浆系统。“拦截”红细胞系统目前正处于临床开发中, 于1991年在美国加州成立，并于1996年在特拉华州重新合并成立。
中文介绍: https://xueqiu.com/S/CERS
Cerus Corp is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
英文介绍: https://www.morningstar.com/stocks/xnas/cers/quote
主题测试文章，只做测试使用。发布者：star，转转请注明出处：https://wallstreetgm.com/cers-cerus-corp/
